Abcam, ab268708, Recombinant human GST-KIF5B Ret (V804L) fusion protein (Active)

Size: 5µg
Recombinant human GST-KIF5B Ret (V804L) fusion protein (Active) is a Human Fragment protein, in the 1 to 575 aa range, expressed in Baculovirus infected Sf9 cells, with >75%, suitable for SDS-PAGE, FuncS.
Key facts
Purity:>75% SDS-PAGE,
Expression system:Baculovirus infected Sf9 cells,
Tags:Tag free,
Applications:FuncS, SDS-PAGESee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:The specific activity of ab268708 was determined to be 49 nmol/min/mg in a kinase assay using IGF1Rtide (KKKSPGEYVNIEFG) synthetic peptide substrate.,
Accession:P33176,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 7.5Constituents: 25% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.79% Tris HCl, 0.31% Glutathione, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.003% EDTA, 0.002% PMSF

Product details:
GST-KIF5B-Ret (V804L) fusion protein.

Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target known as KIF5B-RET is a fusion protein that results from the rearrangement between the KIF5B (kinesin family member 5B) gene and the RET (rearranged during transfection) proto-oncogene. This fusion protein retains the motor domain of KIF5B and the tyrosine kinase domain of RET. KIF5B has a molecular mass of approximately 116 kDa and RET is about 170 kDa when forming its normal protein product. KIF5B is largely expressed in neuronal tissues while RET is commonly found in tissues of the embryonic kidney neural crest derivatives and other neuroepithelial-derived tissues.
Biological function summary
The formation of the KIF5B-RET fusion results in a constitutively active tyrosine kinase leading to unregulated cell signaling. KIF5B-RET is not known to be part of a larger stable protein complex but it initiates signaling pathways essential for cell proliferation and differentiation. The fusion protein hijacks the motor function of KIF5B to position RET inappropriately within the cell which leads to constitutive activation of downstream signaling cascades.
Pathways
The constitutive activity of the KIF5B-RET fusion protein impacts the MAPK (mitogen-activated protein kinase) and PI3K-AKT (phosphoinositide 3-kinase/protein kinase B) signaling pathways. These pathways are critical for regulating cell growth and survival and the KIF5B-RET fusion protein abnormally stimulates them. The natural RET protein associates with ligands such as GDNF (glial cell-derived neurotrophic factor) but the fusion bypasses the need for these ligands resulting in active signaling independent of external cues.
KIF5B-RET is prominently associated with certain types of lung cancer specifically non-small cell lung cancer (NSCLC) and thyroid cancer particularly papillary thyroid carcinoma. The presence of this fusion leads to uncontrolled proliferation of cancerous cells. RET is also connected to other proteins such as ALK (anaplastic lymphoma kinase) in these cancers as they both drive oncogenic pathways leading to tumor development and progression. Identifying KIF5B-RET fusions in tumors has led to targeted therapies aimed at inhibiting its kinase activity.